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ABSTRACT
We recently proposed a new bioinformatic algorithm called OncoFinder for 
quantifying the activation of intracellular signaling pathways. It was proved 
advantageous for minimizing errors of high-throughput gene expression analyses 
and showed strong potential for identifying new biomarkers. Here, for the first time, 
we applied OncoFinder for normal and cancerous tissues of the human bladder to 
identify biomarkers of bladder cancer. Using Illumina HT12v4 microarrays, we profiled 
gene expression in 17 cancer and seven non-cancerous bladder tissue samples. 
These experiments were done in two independent laboratories located in Russia 
and Canada. We calculated pathway activation strength values for the investigated 
transcriptomes and identified signaling pathways that were regulated differently 
in bladder cancer (BC) tissues compared with normal controls. We found, for both 
experimental datasets, 44 signaling pathways that serve as excellent new biomarkers 
of BC, supported by high area under the curve (AUC) values. We conclude that 
the OncoFinder approach is highly efficient in finding new biomarkers for cancer. 
These markers are mathematical functions involving multiple gene products, which 
distinguishes them from “traditional” expression biomarkers that only assess 
concentrations of single genes.
Oncotarget9023www.impactjournals.com/oncotarget
INTRODUCTION 
Bladder cancer (BC) is the second most frequent 
urological cancer and the ninth most common of all 
cancers. Approximately 356,000 new BC cases are 
reported annually worldwide [1], with the majority 
observed in males. BC incidence varies greatly among 
different geographic regions (ranging between 1.8–27.1 
per 100,000 males and 0.5–4.1 per 100,000 females), with 
the highest incidences in countries where the dominant 
population is Caucasoid [2]. BC accounts for 3.1% and 
1.8% of the overall cancer mortality in males and females, 
respectively.
Early diagnosis is a prerequisite for successful BC 
treatment. In advanced stages, the effectiveness of BC 
treatment is dramatically decreased and is associated 
with poor quality of life. In contrast, early diagnosis of 
BC can significantly prolong lifespan as well as quality 
of life. Existing methods of clinical BC diagnostics are, 
in general, not efficient for detecting BC in its early 
stages; as a result, there is an urgent need and opportunity 
to develop novel diagnostic tools that would efficiently 
detect early-stage BC [3-5]. Moreover, associating marker 
expression with successful medical treatment may provide 
clues to a more efficient, patient-oriented cancer treatment 
therapy [6-9].
Recently, we developed a new bioinformatic 
technique called OncoFinder [10-11]. Based on large-
scale transcriptomic data, this novel approach enables 
quantitative measurement of intracellular signaling 
pathway (ISP) activation in many cell/tissue physiological 
and pathological conditions, including cancer. OncoFinder 
operates similarly to another recently published approach 
termed Pathifier [12], which also quantitatively analyzes 
the extent of signaling pathway activation basing on gene 
expression data. However, the Pathifier algorithm utilizes 
different mathematical formulae for calculation of pathway 
activation scores and does not take into account specific 
roles (stimulatory, inhibitory, ambivalent, unknown, 
etc) of individual gene products forming a pathway, 
which may produce a biased output. In OncoFinder, we 
use a manually curated database of molecular signaling 
pathways that includes the functional roles present in a 
pathway [10-11]. 
Signaling pathways regulate all major cellular 
events in health and disease [13-17]. OncoFinder 
calculates a quantitative measurement of the signaling 
pathway activation termed “pathway activation strength” 
(PAS) for the ISPs under investigation. PAS measures the 
cumulative value of perturbations in a signaling pathway 
and may serve as a distinct indicator of pathological 
changes in the intracellular signaling machinery at 
the cellular, tissue, or organ level. In previous studies 
we confirmed the robustness of this approach and its 
applicability to analyzing intracellular signaling [10,18]. 
The PAS calculation algorithm dramatically diminished 
the discrepancies between the microarray and deep 
sequencing data obtained using various experimental 
platforms [19]. The PAS value itself may serve as a new 
type of biomarker that can distinguish between the ISP 
activation profiles in different cancer types [20]. However, 
no such work has been published so far using the PAS 
approach to identify new cancer biomarkers or establish 
signaling pathways relevant to cancer progression. 
In this study, we aimed to evaluate whether PAS 
values serve as efficient markers for human BC or not. 
To this end, we generated gene expression profiles for 
non-cancerous and cancerous bladder tissues using the 
Illumina HT12v4 microarray platform (Illumina, USA) in 
a research laboratory in Moscow, Russia, and in duplicate 
in another laboratory in Lethbridge, Canada. According to 
universal criteria, we compared the two gene expression 
datasets and found 36 new PAS biomarkers for BC with 
high area-under-the-curve (AUC) scores >0.75. We also 
report on a new method of applying the OncoFinder 
algorithm for finding new cancer-specific biomarkers.
RESULTS AND DISCUSSION
Building intracellular signaling pathway 
activation profiles
We investigated gene expression profiles generated 
from 17 clinical BC tissue samples and seven non-
cancerous bladder tissue samples using Illumina human 
HT 12 v4 bead arrays. The bladder cancer patients were 
treated at the P.A. Herzen Oncology Institute (Moscow). 
The non- cancerous tissue samples were taken from 
healthy donors killed in road accidents. To minimize the 
batch effect error, eight cancer and four non-cancerous 
samples were analyzed Dr. Kovalchuk’s laboratory in 
Lethbridge (Canada), and nine cancer and three normal 
bladder tissue samples were analyzed in Dr. Buzdin’s 
laboratory in Moscow (Russia). The hybridization 
signals were quantile normalized according to [21]. 
The normalized gene expression data from Lethbridge 
and Moscow are shown in Supplemental Files 1 and 2, 
respecrively. The data were next processed using the 
OncoFinder algorithm to establish pathway activation 
strength (PAS) profiles. The formula for PAS calculation 
accounts for gene expression data and for information on 
the protein interactions in a pathway, namely, individual 
protein activator or repressor roles in a pathway [10]; 
for pathway p, 
( )∑ ⋅
n
nnpp CNRARR=PAS lg
. The 
relative role of a gene product in signal transduction is 
reflected by a discrete flag activator/repressor role (ARR), 
which equals 1 for an activator gene product, –1 for a 
repressor, and shows intermediate values -0,5; 0,5 and 
0 for the gene products that have repressor, activator, 
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or unknown roles, respectively. The CNRn value (case-
to-normal ratio) is the ratio of the expression level of a 
gene n in the sample under investigation to the average 
expression level in the reference sampling. The positive 
value of PAS indicates abnormal activation of a signaling 
pathway, and the negative value - its repression.
We analyzed activations of 271 intracellular 
signaling pathways. For PAS calculations, the Moscow 
cancer samples were normalized to the averaged Moscow 
normal samples, and Lethbridge cancer samples were 
normalized to the averaged Lethbridge normal samples. 
This type of analysis resulted in a cloud of PAS values 
for cancer samples denoted as PAS(Mos_BC/Mos_norm) 
(Supplemental file 3) and PAS(Leth_BC/Leth_norm) 
(Supplemental file 4). For calculating the cloud of PAS 
values for non-cancerous samples – PAS(Leth_norm/
Mos_norm) (Supplemental file 5) and PAS(Mos_norm/
Leth_norm) (Supplemental file 6) - we used reciprocal 
normalization of the Moscow normal samples to the 
averaged Lethbridge normal samples, and vice versa. 
Assessment of the biomarker potential of PAS
We next investigated if the uncovered signaling 
pathway activation strength values may serve as the 
biomarkers of bladder cancer. To this end, we calculated 
area under the curve (AUC) values. The AUC value is 
the universal test of biomarker robustness. It positively 
correlates with biomarker quality and depends on the 
sensitivity and specificity of a biomarker. AUC may vary 
within an interval from 0.5 to 1. The AUC threshold for 
discriminating good and poor biomarkers is typically 0.7 
or 0.75, with higher AUC scores considered to be good-
quality biomarkers and vice-versa [22]. We calculated 
AUC scores for the comparison of (i) PAS(Mos_BC/Mos_ 
norm) vs PAS(Leth_norm/Mos_norm) and (ii) PAS(Leth_
BC/Leth_norm) vs PAS(Mos_norm/Leth_norm) 
(Supplemental Files 7 and 8 for (i) and (ii), respectively). 
We next compared the results for both obtained AUC 
datasets. We found that many PAS scores showed strong 
AUC values simultaneously in both comparisons. Overall, 
there were 102 pathways with AUC > 0.75 for comparison 
(i) (Supplemental Files 9) and 113 pathways with AUC 
> 0.75 for comparison (ii) (Supplemental Files 10). 
The distributions of the PAS values for the differential 
pathways among cancer vs non-cancer samples is shown 
in Supplemental files 11 and 12 for the comparisons (i) 
and (ii), respectively. 
Of these, 44 top AUC-scoring pathways overlapped, 
which suggests they may serve as efficient BC biomarkers 
(Table 1). The use of two independent gene expression 
profiling procedures (in Moscow and in Lethbridge) 
strengthens the significance of these results. These 
good-quality common markers (AUC > 0.75) showed 
congruent activation patterns in both comparisons (i) 
and (ii), as supported by similar correlation coefficients 
between pathway activation strengths and cancerous/non-
cancerous state of the bladder tissue (Fig. 1). This means 
that in both comparisons the 44 different pathways showed 
similar characteristics of up/downregulation in cancer. 
Among the 44 overlapping PAS biomarkers, 10 (23%) 
were upregulated and 34 (77%) were downregulated in 
BC (Table 1). Eight differential PAS biomarkers (18%) 
represented independent regulatory networks, whereas 
the rest, thirty-six (82%), were terminal branches of larger 
molecular signaling pathways (Table 1).
Biological effect of the differential pathways
The up/downregulation of the 44 differential 
pathways seen in the BC samples could lead to 
contradictory effects on the survival and proliferation 
of cancer cells (Table 2). Information in the literature 
indicates that seven (16%) of the changes in the affected 
pathways promote cancer cell growth, survival, and 
proliferation while 12 (27%) of the changes exert negative 
effects on cancer cells (references shown on Table 2). The 
rest of the pathways play contradictory roles on cancer 
cells, which prevents us from unambiguous labeling them 
as “positive” or “negative” regulators of BC progression 
(Table 2). 
However, overall we observed a clearly enhanced 
proportion of negative BC regulatory changes among the 
marker pathways. This finding may be explained by the 
following general factors in cancer biology. Initial and 
further steps of cancer malignization activate internal 
sensory protective systems of the affected cells, which 
leads to upregulation of the anticancer signaling [23-
26]. Normally, these anticancer changes in intracellular 
signaling should result in decreased proliferation and 
motility, growth and cell cycle arrest, intense proapoptotic 
signaling and pause in biosynthesis. However, cancer 
cells surmount these barriers using a wide variety of 
strategies, e.g., by blocking cell death via induction of 
inhibitor of apoptosis (IAP) proteins like Survivin, and 
by ubiquitination-mediated targeted proteolysis of key 
tumor suppressor proteins [27-30]. These effects act 
in concert with the variety of molecular mechanisms 
that simultaneously promote cancer cell growth and 
proliferation, invasion, and vascularization of cancer 
tissues. Importantly, the activated cancer-promoting 
mechanisms are very diverse among the individual cancer 
cases and may vary greatly among samples, even in the 
same cancer type [31-33]. This illustrates the well-known 
observation that individual cancers are largely unique 
and that personalized approaches are needed to increase 
efficiency of therapy and diagnostics [34-35]. Anticancer 
protective regulatory mechanisms have evolved for 
hundreds of millions of years and represent a conserved set 
of regulatory pathway activation features [36-37]. Cancer-
promoting mechanisms are, in contrast, significantly more 
variable within individual cancer cases as they reflect 
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Table 1: AUC scores of the differential BC-specific pathways for the comparisons (i) -AUC_L and (ii) – AUC_M.
Status in BC Pathway AUC_L AUC_M
Upregulated AHR_Pathway 0,88 0,92
Upregulated AHR_Pathway_C_Myc_Expression 1,00 0,97
Upregulated AHR_Pathway_Cath_Repression 1,00 0,97
Downregulated AKT_Pathway_Cell_Cycle 0,96 0,97
Downregulated Androgen_receptor_Pathway 1,00 0,94
Downregulated Androgen_receptor_Pathway_AR_Degradation 1,00 0,92
Downregulated ATM_Pathway_Apoptosis 1,00 1,00
Downregulated cAMP_Pathway_Endothelial_Cell_Regulation 1,00 0,92
Downregulated cAMP_Pathway_Glycolysis 0,88 1,00
Downregulated CREB_Pathway 1,00 0,97
Downregulated CREB_Pathway_Gene_Expression 0,92 1,00
Upregulated Glucocorticoid_Receptor_Pathway_Cell_cycle_arrest 0,88 0,86
Downregulated GSK3_Pathway_Degradation 1,00 1,00
Downregulated HIF1Alpha_Pathway_Gene_expression 0,96 0,94
Downregulated HIF1Alpha_Pathway_NOS_pathway 0,96 0,97
Downregulated HIF1Alpha_Pathway_Pyruvate 0,96 0,97
Downregulated IGF1R_Signaling_Pathway 1,00 1,00
Downregulated IGF1R_Signaling_Pathway_Cell_survival 1,00 0,97
Downregulated ILK_Pathway_Apoptosis 0,88 0,92
Downregulated ILK_Pathway_Cell_adhesion_cell_motilityopsonization 0,88 0,86
Downregulated ILK_Pathway_Cell_cycle_proliferation 0,88 0,86
Downregulated ILK_Pathway_Cell_migration.retraction 0,88 0,89
Downregulated ILK_Pathway_Cell_motility 0,92 0,92
Downregulated ILK_Pathway_Cytoskeletal_reorganiation 0,88 0,92
Downregulated ILK_Pathway_G2_phase_arrest 0,88 0,86
Downregulated ILK_Pathway_Regulation_ofintermediate_filaments 0,88 0,86
Downregulated ILK_Pathway_Regulation_of_junctionassembly_of_desmosomes 0,88 0,86
Downregulated ILK_Pathway_Wound_healing 0,88 0,86
Downregulated Integrin_SIgnaling_PathwayFocal_adhesion_and_stress_fibers 1,00 1,00
Downregulated IP3_Pathway 1,00 0,89
Downregulated IP3_Pathway_Gene_expression 1,00 1,00
Upregulated JAK_mStat_Pathway_JAK_degradation 1,00 1,00
Downregulated mTOR_Pathway_Translation_on 0,92 0,83
Upregulated mTOR_Pathway_VEGF_pathway 0,96 0,89
Upregulated p53_Signaling_m_Pathway_p53_Degradation 1,00 1,00
Downregulated PAK_Pathway_Myosin_Activation 1,00 1,00
Upregulated RNA_Polymerase_II_Complex_Pathway 1,00 0,89
Downregulated SMAD_Pathway 1,00 0,97
Downregulated TGF_beta_Pathway_Epithelial_mesehchymaltransdifferentiation 0,96 0,97
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Downregulated TGF_beta_Pathway_Post_transcriptionalG1_arrest 1,00 1,00
Upregulated Transition_and_termination_ofDNA_replication_effect 1,00 1,00
Downregulated VEGF_Pathway 1,00 0,92
Downregulated VEGF_Pathway_Actin_Reorganization 1,00 0,92
Upregulated Wnt_Pathway_Ctnn.B_Degradation 1,00 1,00
Table 2: Functional statuses of the marker differential pathways in BC and their overall effects on proliferation of 
cancer cells
Pathway Status in BC Effect on Proliferation References
AHR_Pathway Upregulated  Controversial [39]  
AHR_Pathway_C_Myc_Expression Upregulated  Positive [40-41]  
AHR_Pathway_Cath_D_Repression Upregulated   Controversial [42-43] 
AKT_Pathway_Cell_Cycle Downregulated  Negative [44-45] 
Androgen_receptor_Pathway Downregulated   Controversial [46-47] 
Androgen_receptor_Pathway_AR_Degradation Downregulated   Positive [47-46]
ATM_Pathway_Apoptosis Downregulated   Positive [48-49]
cAMP_Pathway_Endothelial_Cell_Regulation Downregulated   Controversial [50] 
cAMP_Pathway_Glycolysis Downregulated  Negative [51]  
CREB_Pathway Downregulated   Controversial [52-53]  
CREB_Pathway_Gene_Expression Downregulated   Controversial [52-53]
Glucocorticoid_Receptor_Pathway_Cell_cycle_arrest Upregulated   Negative [54]
GSK3_Pathway_ Degradation of  Ctnn_B. Downregulated   Controversial [55-57]
HIF1Alpha_Pathway_Gene_expression Downregulated     Controversial [58]
HIF1Alpha_Pathway_NOS_pathway Downregulated     Controversial [58]
HIF1Alpha_Pathway_Pyruvate Downregulated     Controversial [58]
IGF1R_Signaling_Pathway Downregulated   Negative [59-60] 
IGF1R_Signaling_Pathway_Cell_survival Downregulated   Negative [59-60]
ILK_Pathway_Regulation of Apoptosis Downregulated  Negative [61]
ILK_Pathway_Cell_adhesion_cell_motility
opsonization Downregulated   Controversial [62]
ILK_Pathway_Cell_cycle_proliferation Downregulated  Negative [61]
ILK_Pathway_Cell_migration.retraction Downregulated   Controversial [63]
ILK_Pathway_Cell_motility Downregulated   Controversial [62]
ILK_Pathway_Cytoskeletal_reorganiation Downregulated   Controversial [64]
ILK_Pathway_G2_phase_arrest regulation Downregulated  Negative [65]
ILK_Pathway_Regulation_of_intermediate_filaments Downregulated   Controversial [64]
ILK_Pathway_Regulation_of_junction_assembly
of_desmosomes Downregulated   Controversial [64]
ILK_Pathway_Wound_healing Downregulated   Controversial [64]
Integrin_SIgnaling_Pathway_Focal_adhesion_and_
stress_fibers Downregulated   Controversial  [64]
IP3_Pathway Downregulated   Controversial [66-68] 
IP3_Pathway_Gene_expression Downregulated   Controversial [66-68]
JAK_mStat_Pathway_JAK_degradation Upregulated   Controversial [69-72]   
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mTOR_Pathway_Translation_on Downregulated   Negative [73-74] 
mTOR_Pathway_VEGF_pathway activation Upregulated   Positive [73-74]    
p53_Signaling_m_Pathway_p53_Degradation Upregulated   Positive [75-76] 
PAK_Pathway_Myosin_Activation Downregulated   Controversial [77]
RNA_Polymerase_II_Complex_Pathway Upregulated   Controversial [78]
SMAD_Pathway Downregulated   Positive [79-80] 
TGF_beta_Pathway_Epithelial_mesehchymal_
transdifferentiation Downregulated   Negative [81]
TGF_beta_Pathway_Post_transcriptional_
G1_arrest Downregulated   Positive [81] 
Transition_and_termination_of_DNA_replication_
effect Upregulated   Negative [82-83]  
VEGF_Pathway Downregulated   Negative [84]
VEGF_Pathway_Actin_Reorganization Downregulated   Controversial [84] 
Wnt_Pathway_Ctnn.B_Degradation Upregulated   Controversial [57-58, 85] 
Figure 1: Representation of the Correlation coefficients for pathway activation states depending on the normal/
cancerous nature of BC tissue specimens, calculated for the PAS values of the different intracellular signaling pathways 
for the Comparisons (i) and (ii). Negative correlation coefficients mean downregulation of a pathway in BC, positive – upregulation. 
Correlation Moscow/Moscow means correlation coefficients calculated for the Comparison (i); correlation Leth/Leth means correlation 
coefficients calculated for the Comparison (ii).
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unique deleterious changes of the intracellular regulatory 
network [31-33]. 
Good-quality PAS biomarkers of BC are signaling 
pathway activation features that clearly distinguish cancer 
vs non-cancer bladder tissues. According to the above 
model, PAS biomarkers must be enriched in protective 
(more conserved) changes in intracellular signaling, which 
is in good agreement with our observations for bladder 
cancer. However, this model remains to be further verified 
for other cancer types. 
The functional role for most of the BC-specific 
features of intracellular signaling remains unknown (Table 
2). However, the above theory predicts that many are 
protective cancer suppressor mechanisms. 
CONCLUSION
In this study, for the first time we performed 
large-scale quantitative and qualitative profiling of the 
intracellular signaling pathways, which distinguish normal 
and cancerous tissues. This analysis was carried out for 
human bladder tissues, but the same algorithm can be 
employed to investigate any tissue type or any pathology 
of interest. To determine pathology-specific signaling 
pathways, the following approach is suggested. First, 
one should determine gene expression levels in a pool of 
pathological samples and in a pool of matching normal 
samples. The results obtained for the normal pool are then 
divided into at least two subsets, of which one is used 
as the “normal” reference for the PAS calculation, and 
another is used as the “false-pathological” sampling that 
is formally treated as “pathological” during the application 
of OncoFinder algorithm. The, the clouds of PAS values 
are determined for the true pathological samples and 
for the false-pathological samples, which are compared 
to each other, followed by calculation of AUC scores, 
which support pathology-specific PAS biomarkers. We 
used this approach to identify forty-four new BC-specific 
PAS biomarkers, all of which showed significant AUC 
values. This pool of biomarkers was enriched in anticancer 
protective regulatory features, which is consistent with 
the concept that they are more conserved compared to the 
highly variable tumorigenic molecular mechanisms. 
METHODS
Planning the experimental procedures
Microarray analyses were preformed on tumor 
samples from 17 BC patients treated at the P.A. Herzen 
Moscow Oncological Research Institute. Of these 
samples, nine were examined at the Institute of Bioorganic 
Chemistry (IBC; Moscow, Russia) and eight at the 
University of Lethbridge (UL; Alberta, Canada). All tumor 
samples were examined using Illumina microarrays (series 
Illumina Human HT-12 v4). On each Illumina microchip 
(both at IBC and at UL), we investigated tumor samples 
and the control samples from the intact bladder: three at 
IBC and four at UL. 
Tissue collection and RNA isolation
This study was approved by the local ethical 
committee at Shemyakin-Ovchinnikov IBC. Tissue 
samples from malignant tumors were obtained from 
patients who had undergone surgery for BC at the P.A. 
Hertzen Moscow Clinical Oncology Institute between 
2009 and 2013. All patients provided written informed 
consent to participate in this study. The consent procedure 
was approved by the ethical committee of the P.A. Hertzen 
Moscow Clinical Oncology Institute. Tissue samples from 
non-cancer controls were collected from autopsies at the 
Department of Pathology at the Faculty of Medicine, 
Moscow State University. Both the tumors and normal 
tissues were evaluated by a pathologist to confirm the 
diagnosis and estimate the tumor cell numbers. All tumor 
samples used in this study contained at least 80% tumor 
cells. Tissue samples were immediately stabilized in 
RNAlater (Qiagen, Germany) and then stored at −80°C. 
Seventeen samples from tumors and seven from normal 
bladder tissues were analyzed. The mean age of the cancer 
patients at the time of surgical tumor resection was 64.6 
years, with a median age of 64 years (range 48 –77 years). 
Six patients had stage T1, two had stage T2, six had stage 
T3, and three had stage T4 BC. Grades of disease were 
G1 in one patient, G2 in three, and G3 in 13. Nine of 
17 patients had recurrent tumor growth (Supplemental 
file 13). The mean age of the healthy tissue donors was 
42.11 years, with a median of 45 years (range 20–71 
years). Tissue samples were stabilized in RNAlater and 
then stored at −80°C. Frozen tissue was homogenized 
in TRIzol Reagent (Life Technologies, Inc., CA, USA). 
RNA was isolated following the manufacturer’s protocol. 
Purified RNA was dissolved in RNase-free water and 
stored at −80°C.
Gene expression microarray experiments
A total of 24 tissue samples—17 cancer and seven 
normal bladder mucosa specimens—were selected for 
microarray analysis. Total RNA was extracted using 
TRIzol Reagent and then reverse-transcribed to cDNA and 
cRNA using the Ambion TotalPrep cRNA Amplification 
Kit (Invitrogen, USA). The cRNA concentration was 
quantified and adjusted to 150 ng/ml using an ND-1000 
Spectrophotometer (NanoDrop Technologies, USA). A 
total 750 ng of each RNA library was hybridized onto the 
bead arrays.
Gene expression experiments were performed by 
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Genoanalytica (Moscow, Russia) and the O. Kovalchuk 
Laboratory (Lethbridge, Canada) using the Illumina 
HumanHT-12v4 Expression BeadChip (Illumina, Inc.). 
This gene expression platform contains more than 25,000 
annotated genes and more than 48,000 probes derived 
from the National Center for Biotechnology Information 
RefSeq (build 36.2, release 22) and the UniGene (build 
199) databases. 
Source datasets
The signaling pathways knowledge base developed 
by SABiosciences (http://www.sabiosciences.com/
pathwaycentral.php) was used to determine structures of 
intracellular pathways, which were used for OncoFinder 
as described previously [10,18]. 
Functional annotation of gene expression data
We applied OncoFinder’s original algorithm [10] 
for functional annotation of the primary expression data 
and for calculating PAS scores. The microarray gene 
expression data were quantile normalized according 
to [21]. Our approach to the transcriptome-wide gene 
expression analysis entailed processing of these scores 
using a scheme that considered the overall impact of 
each gene product in the signaling pathway but ignored 
its position in the pathway graph. The formula used to 
calculate the PAS for a given sample and a given pathway 
p is as follows:
( )∑ ⋅⋅Α
n
nnnpp CNRBTIFARR=SP lg
Here the case-to-normal ratio, CNRn, is the ratio 
of expression levels for a gene n in the sample under 
investigation to the same average value of the control 
group of samples. The Boolean flag of BTIF (beyond 
tolerance interval flag) equals zero when the CNR value 
has simultaneously passed the two criteria that demark the 
significantly perturbed expression level from essentially 
normal. The first criterion is the expression level for 
the sample that lies within the tolerance interval, where 
p>0.05. The second criterion is the discrete value of the 
activator/repressor role that equals the following fixed 
values: −1, when the gene/protein n is a repressor of 
pathway excitation; 1, if the gene/protein n is an activator 
of pathway excitation; 0, when the gene/protein n can 
be both an activator and a repressor of the pathway; and 
0.5 and −0.5, respectively, if the gene/protein n is instead 
an activator or repressor of the signaling pathway p, 
respectively. Results for the 271 pathways were obtained 
for each sample (listed in Supplemental Dataset 2). 
Statistical tests were determined using the R software 
package. The AUC values were calculated according to 
[38]. 
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